Man Group’s SpringWorks Therapeutics SWTX Stock Holding History

Man Group’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-248,995	Closed	-$11.7M	–	2456
2025 Q2	$11.7M	Buy	248,995 +231,123	+1,293%	+$10.3M	0.02%	717
2025 Q1	$789K	Buy	+17,872	New	+$823K	﹤0.01%	1648
2024 Q4	–	Sell	-28,904	Closed	-$926K	–	2196
2024 Q3	$926K	Sell	28,904 -27,187	-48%	-$1.02M	﹤0.01%	1518
2024 Q2	$2.11M	Buy	+56,091	New	+$2.36M	0.01%	1322
2022 Q2	–	Hold	0	–	–	–	1577

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Man Group's SWTX Position: Q3 2025 in Review

Man Group sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 248,995 shares — an estimated $11.7M sold.

Man Group first reported a position in SWTX in Q2 2024 and held it in 4 quarters. The position peaked at $11.7M in Q2 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Man Group reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Man Group sold 248,995 SpringWorks Therapeutics shares in Q3 2025, an estimated $11.7M.
Man Group first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 4 quarters.
Man Group's SpringWorks Therapeutics position peaked at $11.7M in Q2 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Man Group's 13F filing for Q3 2025, filed 14 Nov 2025.